Dr. Terrell Stevenson specializes in the care of hospitalized children. She works both at Stanford and Santa Clara Valley Medical Center. She has particular interests in community pediatric hospital medicine (including care of well babies and coverage of NICU/PICU patients), advocacy, the hospitalist's role in comfort care, and teaching medical trainees.
- Pediatric Hospital Medicine
Clinical Assistant Professor, Pediatrics - General Pediatrics
Co-Director of the Community Pediatrics and Child Advocacy Rotation, Stanford (2015 - 2019)
Honors & Awards
Honor Roll for Clinical Teaching, Stanford School of Medicine (2021, 2022)
Honor Roll for Teaching for the Pediatrics Residency Program, Stanford (2021-2022)
Dedication to Excellence Award for the Community Pediatrics and Child Advocacy Rotation, Stanford (June 2017)
The Golden Apple Teaching Award, Stanford (June 2016)
Letter of Teaching Distinction, Stanford School of Medicine (2014, 2017)
Board Certification: American Board of Pediatrics, Pediatric Hospital Medicine (2019)
Residency: Stanford University Medical Center (2014) CA United States of America
Board Certification, Pediatric Hospital Medicine (2019)
Medical Education: University of California at San Francisco School of Medicine (2011) CA
Board Certification: American Board of Pediatrics, Pediatrics (2014)
Pediatric Functional Neurological Disorder: Demographic and Clinical Factors Impacting Care
JOURNAL OF CHILD NEUROLOGY
This is a multicenter retrospective EMR-based chart review of 88 patients aged 3-21 years admitted for evaluation of functional neurologic disorder (FND). We sought to establish characteristics associated with FND, calculate incidence of abnormal neurodiagnostic findings, and determine features associated with variability in workup and treatment. FND patients were 65% female, 40% White, 33% Hispanic, and 88% primarily English speaking with median 13.9 years. We detected variability in management by age, ethnicity, psychiatric comorbidity, and hospital site. Our findings suggest limited utility to CTs in this setting (100% normal) and that workup can be safely informed by physical exam, which predicted abnormal MRI and LP results. We favor screening for adverse childhood experiences in FND patients. Hospitalization may be a rare opportunity for psychiatry contact.
View details for DOI 10.1177/08830738221113899
View details for Web of Science ID 000825063200001
View details for PubMedID 35815864
An Unusual Case of Abdominal Pain and Hyponatremia in a 16-Year-Old Girl With Disordered Eating
2018; 141 (1)
View details for DOI 10.1542/peds.2017-0291
View details for Web of Science ID 000419003300005
Attitudes Toward Smoking Cessation Among Sheltered Homeless Parents
JOURNAL OF COMMUNITY HEALTH
2015; 40 (6): 1140-1148
The prevalence of smoking among homeless adults is approximately 70 %. Cessation programs designed for family shelters should be a high priority given the dangers cigarette smoke poses to children. However, the unique nature of smoking in the family shelter setting remains unstudied. We aimed to assess attitudes toward smoking cessation, and unique barriers and motivators among homeless parents living in family shelters in Northern California. Six focus groups and one interview were conducted (N = 33, ages 23-54). The focus groups and interviews were audiorecorded, transcribed verbatim, and a representative team performed qualitative theme analysis. Eight males and 25 females participated. The following major themes emerged: (1) Most participants intended to quit eventually, citing concern for their children as their primary motivation. (2) Significant barriers to quitting included the ubiquity of cigarette smoking, its central role in social interactions in the family shelter setting, and its importance as a coping mechanism. (3) Participants expressed interest in quitting "cold turkey" and in e-cigarettes, but were skeptical of the patch and pharmacotherapy. (4) Feelings were mixed regarding whether individual, group or family counseling would be most effective. Homeless parents may be uniquely motivated to quit because of their children, but still face significant shelter-based social and environmental barriers to quitting. Successful cessation programs in family shelters must be designed with the unique motivations and barriers of this population in mind.
View details for DOI 10.1007/s10900-015-0040-2
View details for Web of Science ID 000363978000012
View details for PubMedID 25980523
Long-term outcome following pediatric liver transplantation for metabolic disorders
2010; 14 (2): 268-275
In order to determine long-term outcome, including survival, growth and development, following liver transplantation in children with metabolic disorders, we retrospectively reviewed charts of 54 children with metabolic disorders evaluated from 1989-2005 for presenting symptoms, transplantation timing and indications, survival, metabolic parameters, growth, and development. Thirty-three patients underwent liver transplantation (12 received combined liver-kidney transplants) at a median age of 21 months. At a median follow-up of 3.6 yr, patient survival was 100%, and liver and kidney allograft survival was 92%, and 100%, respectively. For the group as a whole, weight Z scores improved and body mass index at follow-up was in the normal range. Two yr post-transplantation, psychomotor development improved significantly (p < 0.01), but mental skills did not; however, both indices were in the low-normal range of development. When compared to patients with biliary atresia, children with metabolic disorders showed significantly lower mental developmental scores at one and two yr post-transplantation (p < 0.05), but psychomotor developmental scores were not significantly different. We conclude that, in patients with metabolic disorders meeting indications for transplantation, liver transplantation or combined liver-kidney transplantation (for those with accompanying renal failure) is associated with excellent long-term survival, improved growth, and improved psychomotor development.
View details for DOI 10.1111/j.1399-3046.2009.01228.x
View details for PubMedID 19671092
The power of language in medicine. Case study: mongolism.
The Pharos of Alpha Omega Alpha-Honor Medical Society. Alpha Omega Alpha
2009; 72 (4): 4-9
View details for PubMedID 19938258
The secret and soul of Marlboro: Phillip Morris and the origins, spread, and denial of nicotine freebasing
AMERICAN JOURNAL OF PUBLIC HEALTH
2008; 98 (7): 1184-1194
Philip Morris and other tobacco companies have been using ammonia in their manufacturing for more than half a century, and for a variety of purposes: to highlight certain flavors, to expand or "puff up" the volume of tobacco, to prepare reconstituted tobacco sheet ("recon"), to denicotinize (reduce the amount of nicotine in) tobacco, and to remove carcinogens. By the early 1960s, however, Philip Morris had also begun using ammonia to "freebase" the nicotine in cigarette smoke, creating low-yield (reduced-tar or -nicotine) cigarettes that still had the nicotine kick necessary to keep customers "satisfied" (i.e., addicted). We show that Philip Morris discovered the virtues of freebasing while analyzing the impact of the ammoniated recon used in Marlboro cigarettes. We also show how Marlboro's commercial success catalyzed efforts by the rest of the tobacco industry to discover its "secret," eventually identified as ammonia technology, and how Philip Morris later exploited the myriad uses of ammonia (e.g., for flavoring and expanding tobacco volume) to defend itself against charges of manipulating the nicotine deliveries of its cigarettes.
View details for DOI 10.2105/AJPH.2007.21657
View details for Web of Science ID 000257202700012
View details for PubMedID 18511721
View details for PubMedCentralID PMC2424107